[Sleep disorders in Alzheimer's disease].
K A Kolmakova1, V Yu Lobzin1,2, A Yu Emelin1,2
1S.M. Kirov Military Medical Academy, St. Petersburg, Russia.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
|April 29, 2026
Summary
Sleep disturbances in Alzheimer's disease (AD) can worsen neurodegeneration. This review examines AD sleep issues, their mechanisms, and therapeutic strategies, including memantine, to improve cognition and sleep.
Area of Science:
- Neuroscience
- Gerontology
- Sleep Medicine
Background:
- Sleep disturbances are common in Alzheimer's disease (AD).
- These sleep issues may accelerate neurodegenerative processes.
- Understanding the link between sleep and AD progression is crucial.
Purpose of the Study:
- To investigate the progression of sleep disturbances in Alzheimer's disease (AD).
- To explore mechanisms linking sleep disturbances to accelerated neurodegeneration.
- To review therapeutic interventions for sleep disorders in AD patients.
Main Methods:
- Analysis of electrophysiological patterns from polysomnography in AD patients.
- Review of non-pharmacological therapies (CBT, relaxation, sleep hygiene).
- Evaluation of pharmacological treatments, considering risks in elderly patients.
Main Results:
- Specific polysomnographic findings in AD with sleep disorders are identified.
- Non-pharmacological approaches like CBT and sleep hygiene are emphasized.
- Careful pharmacological selection is needed due to adverse effects; memantine shows promise.
Conclusions:
- Sleep disturbances significantly impact Alzheimer's disease progression.
- A combination of non-pharmacological and cautious pharmacological strategies is recommended.
- Memantine may offer benefits for both cognitive function and sleep quality in AD.
Related Concept Videos
01:15REM Sleep Behavior Disorder
2.9K
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
RBD is significantly associated with...
2.9K
01:17Sleepwalking and Sleep Talking
1.8K
Somnambulism, commonly known as sleepwalking, involves individuals engaging in activities ranging from simple walking to more complex behaviors such as driving. Sleepwalking typically occurs during the slow-wave sleep stages 3 and 4 early in the night when the person is not dreaming, contradicting the myth that sleepwalkers are acting out their dreams.
Factors that increase the likelihood of sleepwalking include sleep deprivation and alcohol consumption. Contrary to common beliefs, it is safe...
Factors that increase the likelihood of sleepwalking include sleep deprivation and alcohol consumption. Contrary to common beliefs, it is safe...
1.8K
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
01:23Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K